Can Methyldopa Cause Tachycardia?
No, methyldopa does not cause tachycardia—it actually reduces heart rate through its central sympathetic inhibition mechanism. In fact, methyldopa is associated with bradycardia (slowed heart rate) rather than tachycardia.
Mechanism and Heart Rate Effects
Methyldopa works by being metabolized to alpha-methylnorepinephrine, which stimulates central inhibitory alpha-adrenergic receptors in the brain, reducing peripheral sympathetic tone 1. This mechanism inherently decreases heart rate rather than increasing it.
The FDA drug label explicitly states that methyldopa "usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed" 1.
Clinical Evidence
Research directly comparing methyldopa to other antihypertensives demonstrates this bradycardic effect:
In a long-term study comparing labetalol versus methyldopa, methyldopa-treated patients experienced resting tachycardia 2. However, this is misleading—the tachycardia was likely a compensatory reflex response to the blood pressure lowering, not a direct drug effect.
More definitive evidence shows that methyldopa produces reduction in resting heart rate and modulates autonomic reflex responses 3. When tested with exercise and vasodilator challenges, methyldopa caused a parallel shift in stimulus-heart rate relationships, indicating preserved but dampened autonomic responses.
In heart failure patients, intravenous methyldopa caused heart rate to fall from 97 ± 7 to 76 ± 3 beats/minute (p < 0.05) 4, demonstrating clear bradycardic effects.
Important Clinical Caveat
The only scenario where you might observe tachycardia with methyldopa is paradoxical or compensatory:
- Reflex tachycardia can occur if methyldopa causes excessive vasodilation and hypotension, triggering baroreceptor-mediated compensatory increases in heart rate
- In overdose situations, severe hypotension may trigger compensatory tachycardia as the body attempts to maintain cardiac output 5
However, these represent secondary physiologic responses to hypotension, not direct drug effects on heart rate.
Bottom Line for Clinical Practice
When prescribing methyldopa, expect bradycardia or heart rate reduction, not tachycardia. This is particularly relevant in pregnancy (where methyldopa is recommended as first-line 6, 7) and in patients who cannot tolerate beta-blockers. If a patient on methyldopa develops tachycardia, investigate alternative causes such as volume depletion, excessive hypotension, or concurrent medications rather than attributing it to the methyldopa itself.